Non - alcoholic fatty liver disease and enteral insufficiency: comorbidity of their development


Cite item

Full Text

Abstract

The article reflects current literature data on the epidemiology and risk factors of non - alcoholic fatty liver disease. An important aspect is the description of the modern views of combined lesions of the hepatobiliary tract and small intestine. Disorders of the intestinal microbiota play a special role in the development of non - alcoholic fatty liver disease. The value of enterohepatic circulation of bile acids in the development of intestinal and liver diseases was shown. It seems relevant to further study the comorbidity of the development of non - alcoholic fatty liver disease and enteropathy for the development of pathogenetically substantiated therapy.

About the authors

Ya M Vakhrushev

Izhevsk State Medical Academy

Izhevsk, Russia

E V Suchkova

Izhevsk State Medical Academy

Izhevsk, Russia

A P Lukashevich

Izhevsk State Medical Academy

Izhevsk, Russia

References

  1. Drapkina O, Ivashkin V. Prevalence of Non - alcoholic Fatty Liver Disease in the Russian Federation: the Open, Multicenter, Prospective Study, DIREG 1. Clin Med Res. 2015;3(2):31-6. doi: 10.12691/ajcmr- 3- 2-3
  2. Ивашкин В.Т., Маевская М.В., Павлов Ч.С. Клинические рекомендации по диагностике и лечению неалкогольной жировой болезни Российского общества по изучению печени и Российской гастроэнтерологической ассоциации. Клинические перспективы гастроэнтерологии, гепатологии. 2012;(1):3-9.
  3. De Alwis N.M, Day C.P. Nonalcoholic fatty liver disease: the mist gradually clears. J Hepatol. 2008;48(1):104-12. doi: 10.1016/j.jhep.2008.01.009
  4. Lazo M, Hernaez R, Bonekamp S, Kamel I.R, Brancati F.L, Guallar E, Clark J.M. Non - alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:6891. doi: 10.1136/bmj.d6891
  5. Tacuma Y, Nouso Y. Nonalcoholic steatohepatitis associated hepatocellular carcinoma: our case series and literature review. Wld J Gastroenterol. 2010;16(12):1436-41. doi: 10.3748/wjg.v16.i12.1436
  6. Waly R.S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus of different aspects of management. ISRN Oncol. 2012;2012:1-12. doi: 10.5402/2012/421673
  7. White D.L, Kanwal F, El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol. 2012;10:1342. doi: 10.1016/ j.cgh.2012.10.001
  8. Yang J.D, Roberts L.R. Epidemiology and management of hepatocellular carcinoma. Infect Dis Clin North Am. 2010;24(4):899-919. doi: 10.1016/j.idc.2010.07.004
  9. Argo C.K, Northup P.G, Al-Osaimi A.M, Caldwell S.H. Systematic review of risk factors for fibrosis progression in non - alcoholic steatohepatitis. J Hepatol. 2009;51:371. doi: 10.1016/j.jhep.2009.03.019
  10. Mc Cullough A.J. The epidemiology and risk factors of NASH. Hepatology. 2013;58(5):1644-54. doi: 10.1002/9780470987438.ch3
  11. Duvnjak M, Lerotic I, Barsic N. Patogenesis and management issues for non - alcoholik fatty liver disease. World J Gastroenterol. 2007;13(34):4539-50. doi: 10.3748/wjg.v13.i34.4539
  12. Atabek M.E. Non - alcoholic fatty liver disease and metabolic syndrome in obese children. J Gastroenterol. 2011;17(39):4445. doi: 10.3748/wjg.v17.i39.4445
  13. Ahmed A, Perumpail R.B, Harrison S.A. Hige prevalence of hepatic fibrosis in the setting of coexisting diabetes and hepatic steatosis: A case for selective screening in the general population? Hepatology. 2016;63(1):20-2. doi: 10.1002/hep.28277
  14. Gerskowitch V.P, Hodge J, Hull R.A.D, Shankley N.P, Kalindjian S.B, Mc Ewen J, Black J.W. Unexpected relationship between plasma protein binding and the pharmacodynamics of 2-NAP, a CCK1-receptor antagonist. Br J Clin Pharmacol. 2007;63(5):618-22. doi: 10.1111/j.1365-2125.2006.02789.x
  15. Williamson R.M, Price J.F, Glance S, Perry E, Nee L.D, Hayes P.C, et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care. 2011;34:1139-44. doi: 10.2337/dc10-2229
  16. Doycheva I, Cui J, Nguyen P, Costa E.A, Hooker J, Hoffich H, Bettencourt R, Brouha S, Sirlin C.B, Loomba R. Non - invasive screening of diabetics in primary care for NAFLD and advanced fibrosis by MRI and MRE. Aliment Pharmacol Ther. 2015;43(1):83-95. doi: 10.1111/apt.13405
  17. Ekstedt M, Hagstrom H, Nasr P, Fredrikson M, Kechagias S, Hultcrantz R. Fibrosis Stage is the strongest predictor for disease - specific mortality in NAFLD After Up to 33 Years of Follow-Up. Hepatology. 2015;61(5):1547-54. doi: 10.1016/j.jhep.2015.11.004
  18. Ertle J, Dechene A, Sowa J.P, Penndorf V, Herzer K, Kaiser G, Schlaak J.F, Gerken G, Syn W.K, Canbay A. Non - alcoholic fatty liver disease progress tu hepatocellular carcinoma in the absence of apparent cirrhosis. Int J Cancer. 2011;128:2436-43. doi: 10.1002/ijc.25797
  19. Loomba R, Sanyal A.J. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol. 2013;10:686-90. doi: 10.1038/nrgastro.2013.171
  20. Michelotti G.A, Machado M.V. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol. 2013;10:656-60. doi: 10.1038/nrgastro.2013.183
  21. Stickel F, Hellerbrand С. Non - alcoholic fatty liver disease as a risk factor for hepatocellular carcinoma: mechanisms and implications. Gut. 2010;59:1303-7. doi: 10.1136/gut.2009.199661
  22. Подымова С.Д. Болезни печени: руководство для врачей. Изд. 5-е, перераб. и доп. М.: МИА, 2018.
  23. Younossi Z.M, Koenig A.B, Abdelatif D.A, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease - Meta - analytic assement of prevalence, incidence and outcomes. Hepatology. 2016;64(1):73-84. doi: 10.1002/hep.28431
  24. Copaci I, Mindrut E, Micu L, Hortopan M, Voiculescu M. Can disease progression in non - alcoholic steatohepatitis be stopped? J Hepatol. 2009;50(1):S358. doi: 10.1016/s0168-8278(09)60989-2
  25. Miura K, Ohnishi H. Role of gut microbiota and Toll - like receptors in nonalcoholic fatty liver disease. World J Gastroenterol. 2014;20(23):7381-91. doi: 10.3748/wjg.v20.i23.7381
  26. Rolfe L.D. Interactions among microorganisms of the indigenous intestinal flora and their influence on the host. Rev Infect Dis. 1984;6(1):73-9. doi: 10.1093/clinids/6.Supplement_1.S73
  27. Mouzaki M, Comelli E.M, Arendt B.M, Bonengel J, Fang S.K, Fischer S.E, Mc Gilvray I.D, Allard J.P. Intestinal microbiota in patients with nonalcoholic fatty liver disease. Hepatology. 2013;58:120-7. doi: 10.1002/hep.26319
  28. Zhu L, Baker S.S, Gill C, Liu W, Alkhouri R, et al. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2012;57:601-9. doi: 10.1002/hep.26093
  29. Erejuwa O.O, Sulaiman S.A, Wahab M.S.W. Modulation of gut microbiota in the management of metabolic disorders: the prospects and challenges. Int J Mol Sci. 2014;15:4158-88. doi: 10.3390/ijms15034158
  30. Backhed F, Manchester J.K, Semenkovich C.F, Gordon J.I. Mechanisms underlying the resistance to diet - induced obesity in germfree mice. Proc Natl Acad Sci USA. 2007;104:979-84. doi: 10.1073/pnas.0605374104
  31. Wigg A.J, Roberts-Thomson I.C, Dymock R.B, Mc Carthy PJ, Grose R.H, Cummins A.G. The role small intestinal bacterial overgrowth, intestinal permeability, endotoxaemia and tumor necrosis factor - alfa in a pathogenesis of nonalcoholic steatohepatitis. Gut. 2001;48:206-11. doi: 10.1136/gut.48.2.206
  32. Wieland A, Frank D.N, Harnke B, Bambha A. Systematic review: microbial dysbiosis and nonalcoholic fatty liver desease. Aliment Pharmacol Ther. 2015;42(9):1051-63. doi: 10.1111/apt.13376
  33. Schnabl B. Linking intestinal homeostasis and liver disease. Curr Opin Gastroenterol. 2013;29(3):264-70. doi: 10.1097/mog.0b013e32835ff948
  34. Kim K.A, Gu W, Lee I.A, Joh E.H, Kim D.H. High fat diet - induced gut microbiota exacerbates inflammation and obesity in mice via the TLR4 signaling pathway. PLoS One. 2012;7(10):e47713. doi: 10.1371/journal.pone.0047713
  35. Rivera C.A, Adegboyega P.N, Van Rooijen N, Tagalicud A., Allman M. Toll - like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non - alcoholic steatohepatitis. J Hepatol. 2007;47(4):571-9. doi: 1016/j.hep.2007.04/019
  36. Vance D.E. Role of phosphatidylcholine biosynthesis in the regulation of lipoprotein homeostasis. Curr Opin Lipidol. 2008;19(3):223-34. doi: 10.1097/MOL.0b013e3282fee935
  37. Buchman A.L, Dubin M.D, Moucarzel A.A, Jenden D.J, Roch M, Rice K.M, Gornbein J, Ament M.E. Choline deficiency: a cause of hepatic steatosis during parenteral nutrition that can be reversed with intra - venous choline supplementation. Hepatology. 1995;22:1399-403. doi: 10.1016/0270-9139(95)90143-4
  38. Corbin K.D, Zeisel S.H. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol. 2012;28(2):159-65. doi: 10.1097/MOG.0b013e32834e7b4b
  39. Csak T, Velayudham A, Hritz I, Petrasek J, Levin L, Lippai D, Catalano D, Mandrekar P, Dolganiuc A, Kurt-Jones E, Szabo G. Deficiency in myeloid differentiation factor-2 and toll - like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis. Am J Physiol Gastrointest Liver Physiol. 2001;300(3):433-41. doi: 10.1152/ajpgi.00163.2009
  40. Селиверстов П., Радченко В., Сафроненкова И., Ситкин С. Взаимоотношения печени и кишечника на фоне дисбаланса микрофлоры толстой кишки. Врач. 2009;(10):27-31.
  41. Вахрушев Я.М., Лукашевич А.П. Особенности нарушений пищеварения, всасывания и микробиоценоза в кишечнике у больных желчнокаменной болезнью. Терапевтический архив. 2017;(2):28-32. doi: 10.17116/terarkh201789228-32
  42. Al-Attas O, Al-Daghri N, Al-Rubeaan K. Changes in endotoxin levels in T2DM subjects on antidiabetic therapias. Cardiovasc Diabet. 2009;8:20-29. doi: 10.1186/1475-2840-8-20
  43. Rodes N, Khan A, Paul A, Coussa-Charley M, Marinescu D, Tomaro-Duchesneau C, Shao W, Kahouli I, Prakash S. Effect of probiotics Lactobacillus and Bifidobacteriumon gutderived lypopolysaccharides and inflammatory cytokines: an in vitro study using a human colonic microbiota model. J Microbiol Biotechnol. 2013;23:518-26. doi: 10.4014/jmb.1205.05018
  44. Arumugam M, Raes J, Pelletier Е, et al. Enterotypes of the human gut microbiome. Nature. 2011;473:174-80. doi: 10.1038/nature09944
  45. Селиверстов П.В., Ситкин С.И., Радченко В.Г. Роль дисбиоза кишечника в развитии митохондриальной дисфункции и неалкогольной жировой болезни печени. Медицинский совет. Гастроэнтерология. 2018;(6):90-5. doi: 10.21518/2079-701X-2018-6- 89-95
  46. Немцов Л.М. Синдром избыточного бактериального роста в кишечнике при заболеваниях печени. Здравоохранение. 2015;(4):26-34.
  47. Fuchs C, Claudel T, Trauner M. Bile acid - mediated control of liver triglycerides. Semin Liver Dis. 2013;33(4):330-42. doi: 10.1055/s-0033-1358520
  48. Conradas V.M, Jorens P.J, De Clerck L.S, Van Saene H.K, Ieven M.M, Bosmans J.M, Schuerwegh A, Bridts C.H, Wuyts F, Stevens W.J, Anker S.D, Rauchhaus M, Vrints C.J. Selectiv intestinal decontamination in advanced chronic heart failure: a pilot trial. Eur J Heart Fail. 2004;6(4):483-91. doi: org/10.1016/j.ejheart.2003.12.004
  49. Вахрушев Я.М., Горбунов А.Ю., Тронина Д.В., Сучкова Е.В., Ляпина М.В., Хохлачева Н.А. Желчнокаменная болезнь как возможное проявление системной патологии органов пищеварения. Терапевтический архив. 2015;87(2):54-8. doi: 10.17116/terarkh201587254-58
  50. Hylemon P.B, Zhou H.P, Pandak W.M, Ren S.L, Git G, Dent P. Bile acids as regulatory molecules. J Lipid Res. 2009;50(8):1509-20. doi: 10.1194/jlr.R900007-JLR200
  51. Claudel T, Staels B, Kuipers F. The Farnesoid X receptor - A molecular link between bile acid and glucose metabolism. Arterioscler Thromb Vasc. 2005;25(10):2020-31. doi: 10.1161/01.ATV.0000178994.21828.a7
  52. Matsubara T, Li F, Gonzalez F.J. FXR signaling in the enterohepatic system. Mol Cell Endocrinol. 2013;368(1-2):17-29. doi: 10.1061/j.mce.2012.05.004
  53. Sayin S.I, Wahlstrom A, Felin J, Jantty S, Marschall H.U, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. Gut Microbiota Regulates Bile Acid Metabolism by Reducing the levels of Tauro - β - muricholic Acid, a Naturally Occurring FXR Antagonist. Cell Metab. 2013;368(1-2):17-29. doi: 10.1061/j.cmet.2013.01.003
  54. Li F, Jiang C.T, Krauze K.W, Li Y.F, Albert I, Hao H.P, Fabre K.M, Mitchell J.B, Patterson A.D, Gonzalez F.J. Microbiome remodeling leads tu inhibition of intestinal farnesoid X receptor signaling and decreased obesity. Nat Commun. 2013;4:2384. doi: 10.1038/ncomms.3384
  55. Zhang Y, Lee F.Y, Barrera G, Lee H, Vales C, Gonzalez F.J, Willson T.M, Edwards P.A. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci. 2006;103(4):1006-11. doi: 10.1073/pnas.0506982103
  56. Маевская Е.А., Черемушкин С.В., Кривобородова Н.А., Кучерявый Ю.А. Синдром избыточного бактериального роста в тонкой кишке: от последних научных данных к рутинной практике. Клинические перспективы гастроэнтерологии, гепатологии. 2013;(5):29-40.
  57. Ильченко А.А. Болезни желчного пузыря и желчных путей: руководство для врачей. М.: МИА, 2011.
  58. Вахрушев Я.М., Лукашевич А.П., Горбунов А.Ю., Пенкина И.А. Интестинальные механизмы в нарушении энтерогепатической циркуляции желчных кислот при желчнокаменной болезни. Вестник Российской академии медицинских наук. 2017;72(2):105-11. doi: 10.15690/vramn807
  59. Савельев В.С., Петухов В.А. Желчнокаменная болезнь и синдром нарушенного пищеварения. М.: Боргес, 2011.
  60. Чукаева И.И., Самородская И.В., Ларина В.Н. Сочетанная патология: дискуссионные вопросы терминологии, учета и влияния на выбор тактики ведения пациента. Терапевтический архив. 2018;90(8):125-30

Copyright (c) 2019 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies